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SUMMARY
Cell migration through the brain parenchyma under-
pins neurogenesis and glioblastoma (GBM) develop-
ment. Since GBM cells and neuroblasts use the
same migratory routes, mechanisms underlying
migration during neurogenesis and brain cancer
pathogenesis may be similar. Here, we identify a
common pathway controlling cell migration in normal
and neoplastic cells in the CNS. The nuclear scaffold
protein promyelocytic leukemia (PML), a regulator of
forebrain development, promotes neural progenitor/
stem cell (NPC) and neuroblast migration in the adult
mouse brain. The PML pro-migratory role is active
also in transformed mouse NPCs and in human pri-
mary GBM cells. In both normal and neoplastic set-
tings, PML controls cell migration via Polycomb
repressive complex 2 (PRC2)-mediated repression
of Slits, key regulators of axon guidance. Finally, a
PML/SLIT1 axis regulates sensitivity to the PML-tar-
geting drug arsenic trioxide in primary GBM cells.
Taken together, these findings uncover a drug-
targetable molecular axis controlling cell migration
in both normal and neoplastic cells.
INTRODUCTION
In the adult mammalian brain, new neurons and glial cells
continue to be generated in a germinal niche lining the lateral
ventricles (subventricular zone; SVZ) (Urba´n and Guillemot
2014; Lim and Alvarez-Buylla 2016). Within the niche, neural
stem/progenitor cells (NPCs; type B cells) produce transit-ampli-
fying progenitors (type C cells), which, in turn, give rise to neuro-
blasts (type A cells). Neuroblasts migrate rostrally via the rostral
migratory stream (RMS), and once they reach the olfactory bulb
(OB), they integrate into the existing network as interneurons.
The SVZ-RMS-OB migration and differentiation processes are
highly interdependent and serve as the fundamental basis for
generation of OB neurons throughout life.
Accumulating evidence indicates that adult NPCs and/or type
C cells serve as cells of origin of glioblastoma multiforme (GBM),
one of the most aggressive human cancers (Sanai et al., 2005;
Jacques et al., 2010; Zong et al., 2015). Two of the main factors
underlying GBM aggressiveness are the unrestrained prolifera-
tion and migratory properties of transformed cells (Furnari
et al., 2007; Cuddapah et al., 2014). Several studies have impli-
cated genetic inactivation of tumor-suppressive checkpoints,
such as pRb and p53 in driving tumor growth (Zhu et al., 2005;
Jacques et al., 2010). However, our understanding of the mech-
anisms underlying GBM spreading is limited, due to the infre-
quency of mutations in the very key regulators of cell migration.
GBM cells use the same migratory routes (e.g., blood vessels,
myelin tracts) as neuroblasts and neurons (Arvidsson et al.,
2002; Goings et al., 2004; Zhang et al., 2007; Faiz et al., 2015),
suggesting that the underlying mechanisms may be similar (Wu
et al., 1999; Conover et al., 2000; Nakada et al., 2004; Mertsch
et al., 2008; Itoh et al., 2013; Cuddapah et al., 2014; Naus
et al., 2016).
We have previously implicated the growth suppressor pro-
myelocytic leukemia protein (PML) in cell-fate control during
neocortex development (Regad et al., 2009). PML is found at
the t(15;17) chromosomal translocation of acute promyelocytic
leukemia (APL), which generates the APL PML-RARa oncogene
(de The´ et al., 2012). PML is essential for the formation of a
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nuclear subdomain of the interchromatin space termed the
‘‘PML-nuclear body (PML-NB),’’ which is disrupted in APL and
functions as a nuclear regulatory hub via interaction with tran-
scription factors and chromatin regulators (von Mikecz et al.,
2000; Salomoni and Pandolfi 2002; Bernardi and Pandolfi
2007; Torok et al., 2009; Sahin et al., 2014). In this respect, we
showed that, in the developing cortex, PML restricts radial glial
cell expansion via regulation of pRb phosphorylation with impli-
cations for brain size (Regad et al., 2009) and brain function (But-
ler et al., 2013; Korb and Finkbeiner 2013; Korb et al., 2013).
PML-mediated control of pRb and p53 contributes to the induc-
tion of cellular senescence and tumor suppression downstream
of oncogenic RAS (Alcalay et al., 1998; Fogal et al., 2000; Guo
et al., 2000; Pearson et al., 2000; Vernier et al., 2011; Acevedo
et al., 2016). Accordingly, PML expression is decreased in
human cancers of multiple histological origins (Gurrieri et al.,
2004). However, PML may bear oncogenic functions in estab-
lished tumors via its ability to control cancer stem cell self-
renewal via multiple mechanisms (Ito et al., 2008, 2012; Carra-
cedo et al., 2012).
Here, we identify PML as a positive regulator of cell migration
in both normal NPCs and primary human GBM cells indepen-
dently of its ability to control proliferation and via repression of
the Slit axon guidance genes. PML represses the expression of
Slit genes in both normal and neoplastic cells via modulation of
levels and distribution of the repressive H3K27me3mark. Finally,
the PML/SLIT1 axis regulates sensitivity of primary human GBM
cells to the PML-targeting drug As2O3. Overall, these findings
reveal a novel and potentially targetable PML/Slit pathway
involved in regulation of cell migration in both normal and
neoplastic cells in the adult brain.
RESULTS
PML Loss Leads to Reduced Number of Stem Cells and
Increased Number of Progenitors in the SVZ
Based on our previous work implicating PML in embryonic
neurogenesis, we set out to investigate its role in the regula-
tion of adult neurogenesis within the SVZ/OB niche. In adult
(6-month-old) PML+/ mice, PML was expressed in a number
of glial fibrillary protein+ (GFAP) and GFAP cells in the SVZ,
suggesting that it is expressed in astroglial NPCs (Figure S1A).
We then performed fate-mapping experiments based on serial
5-ethynyl-20-deoxyuridine (EdU) injections. Mice were sacri-
ficed either 1 month (identifying differentiated progeny in the
OB and label-retaining NPCs in the SVZ; Figure 1A) or 1 day
(identifying predominantly cycling type C cells in the SVZ
and early-born neuroblasts (Figure 1B) after the last EdU
injection. PML expression was detected in approximately
30%–40% of EdU+/GFAP+ NPCs within the SVZ at 1-month
and 1-day chase (see graph next to Figures 1A and 1B).
PML was expressed also in doublecortin (DCX)+ migratory
neuroblasts (Figure 1C). PML expression in NPCs was
confirmed in vitro using Nestin+ NPCs derived from the SVZ
and grown either adherently (Figure 1D) or as neurospheres
(Figure 1E). PML expression was gradually downregulated at
both the transcript and protein levels upon induction of differ-
entiation (Figures S1B and S1C) and was virtually absent in
bIII-tubulin (TuJIII) (neurons) and GFAP (glia) terminally differ-
entiated cells (Figures 1F and S1C).
To determine the role of PML controls during adult neurogen-
esis, we performed fate-mapping experiments using a germline
PML knockout (KO) model (Regad et al., 2009; Butler et al., 2013;
Korb and Finkbeiner 2013; Korb et al., 2013). As previously
observed (Regad et al., 2009), the appearance and brain size
of PML+/+ and PML+/ mice were undistinguishable (data not
shown). Adult PML+/ and PML/ mice were injected intraper-
itoneally with EdU as described earlier. Analysis of EdU+ cells
after 1-month chase showed a significant reduction in the
number of label-retaining cells (type B cells) in PML/ SVZ
compared to control mice (Figure 2A). In contrast, at 1-day
chase, PML/ mice displayed significantly more EdU+ cells
(predominantly type C cells) in the SVZ (Figure 2B).
Loss of PML Leads to Reduction in Neuroblast
Migration, Differentiation, and Olfactory Bulb Size
To investigate whether an increase in type C cells correlated
with augmented neuroblast number, we examined the number
of migratory neuroblasts in the RMS of PML+/ and PML/
mice at 1-day chase. Staining for DCX and EdU, indeed,
revealed a greater number of migratory neuroblasts in the pos-
terior RMS (RMSp) of PML/ mice (Figure 3A). However, fewer
migratory neuroblasts were found in the RMS region proximal
to the OB (RMSob) in PML/ mice (Figure 3B), suggesting a
defect in RMS/OB migration, despite increased entry into dif-
ferentiation. This correlated with a reduction in the number of
newly differentiated (EdU+) neurons in the OB of PML/
mice at 1-month chase (Figure 3C). This reduction correlated
with a reduced OB size in PML/ mice compared to that in
PML+/ mice (Figures 3D and 3E), while OB size in PML+/+
mice and PML+/ mice was indistinguishable (Figures S2A
and S2B).
PML-Deficient NPCs Display Increased Cell
Proliferation and Reduced Cell Migration In Vitro
In order to determine the intrinsic nature of phenotypic changes
observed in vivo and to investigate the underlying molecular
mechanisms, we used an in vitro system based on NPCs derived
from the SVZ of adult (6-month-old) mice. NPCs, themselves,
can acquire migratory properties upon injury or neoplastic trans-
formation (Arvidsson et al., 2002; Goings et al., 2004; Zhang
et al., 2007; Faiz et al., 2015; Giachino et al., 2015). When plated
at clonal density, PML/ cells formed larger neurospheres
(220.8 mm) than control cells (127.8 mm) (Figure S3A). Further-
more, adherent PML/ cultures displayed a higher percentage
of EdU+ cells (Figure S3B). Finally, at late passages,PML/ cells
had a reduced number of EdU+ cells, suggesting an exhaustion
phenotype, which correlates with the reduction in label-retaining
cells in the SVZ of PML-deficient mice (Figure S3C). As observed
in vivo, PML/ cells are impaired in migration using transwell
assays (Figure 3F). Moreover, cells derived from a PML knockin
mutant mouse (Cys62Ala/Cys65Ala; PML RingMut) lacking
PML-NBs (Voisset et al., 2016) displayed a migration defect
similar to that of PML/ cells (Figure 3G), suggesting that
the pro-migratory role of PML is PML-NB dependent. Finally,
supernatants from PML/ cultures impaired the migration
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capacity of PML+/ cells, potentially implicating a soluble factor
(or factors) in the cell-migratory phenotype of PML-deficient cells
(Figure 3H).
PML Controls Cell Migration through Repression of the
Axon Guidance Slit2 Gene
As pRb/E2F3 regulates migration of interneurons during cortical
development in a cell-cycle-independent manner (McClellan
et al., 2007), we first tested whether PML controls migration
via pRb. In adult NPCs, PML loss resulted in increased pRb
phosphorylation and decreased p53 and p21 expression at
steady state (Figures S4A and S4B). However, induction
of p53 and p21 upon ionizing radiation was unaffected (Fig-
ure S4B). Inhibition of pRb and p53 via expression of Simian
virus 40 (SV40) large T (LT) antigen did not inhibit but rather
increased extracellular matrix (ECM) migration in PML+/ cells
A
B
C D
E F
Figure 1. PML Is Expressed in Adult Astroglial NPCs In Vivo and In Vitro
(A and B) Shown here: PML expression (A) in quiescent NPCs (1-month chase) and (B) in committed NPCs (1-day chase). Scale bars, 50 mm. Bar plots represent
the quantification of EdU+/GFAP+ and EdU+/GFAP+/PML+ cells at 1-day chase and 1-month chase, respectively.
(C) PML expression in EdU/DCX+ migratory neuroblasts. Scale bars, 50 mm.
(D and E) In vitro PML immunostaining in single adherent NPCs and whole neurospheres. Scale bars, 25 mm in (D) and 50 mm in (E).
(F) Decreased expression of PML in differentiating NPCs identified by co-staining of TuJIII and GFAP. Scale bar, 20 mm.
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(Figure S4D), suggesting (1) that increased proliferation per
se is not sufficient to inhibit NPC migration and (2) that
the migration defect caused by PML loss is p53 and pRb
independent.
To investigate alternative mechanisms, we analyzed the
expression of a panel of genes involved in positive or negative
regulation of cell migration that are known to play a role in cell
migration in the CNS (Slit/Robo gene family members, epithe-
lial-mesenchymal transition factors, and metalloproteinases)
(Figures 4A and S4E–S4G). Among the genes analyzed, the
Slit2 gene was found to be significantly upregulated in PML/
cells (Figure 4A). Slit2 belongs to an evolutionary conserved
family of glycoproteins with chemorepellent activity, which reg-
ulates axon guidance in flies and the mouse CNS by binding to
Figure 2. PML Controls Stem Cell Fate
during Adult Neurogenesis
(A and B) As shown here, (A) decreased number
of label-retaining NPCs (type B cells) and (B)
increased number of type C cells within the SVZ in
PML/ compared to PML+/ mice. Bar plots
represent the mean number of EdU+ nuclei per
SVZ per each genotype. Data are represented as
mean ± SEM of n = 3; *p < 0.05; **p < 0.01;
unpaired t test. Scale bars, 50 mm. Images are
stitched together to visualize the lateral ventricle.
their cognate Robo receptors (Brose
et al., 1999; Li et al., 1999; Nguyen-Ba-
Charvet et al., 2004; Kaneko et al.,
2010; Borrell et al., 2012; Blockus and
Che´dotal 2014). Slit2 binding to Robo1
has been shown to inhibit cell migra-
tion in the RMS (Nguyen-Ba-Charvet
et al., 2004). Robo1, itself, was signifi-
cantly, albeit marginally, upregulated in
PML-deficient NPCs (Figure S4E). Slit2
was upregulated in 4-hydroxytamoxifen
(4-OHT)-treated p-MIG-Cre-ERT2-GFP
PMLF/F NPCs (Figures 4B and S4H–
S4J). Slit2 protein levels were also
increased in both germline and condi-
tional PML knockout models (Figures
4C and 4D). Finally, SV40 LT did not
increase Slit2 expression in PML+/ cells
(Figure S4K), in agreement with ECM
migration data (Figure S4D).
To test whether Slit2 regulates cell
migration downstream of PML, we per-
formed ECM migration assays using re-
combinant Slit1 and Slit2 proteins (rSlit1
and rSlit2). rSlit2 inhibited migration in
PML+/ cells, but it did not exacerbate
the migration defect observed in PML/
cells. Conversely, a His-tagged Robo1
deletion mutant (Robo1N), which acts as
a decoy soluble receptor, rescued the
cell-migration defect of PML/ NPCs,
and this effect was abolished by the addition of rSlit2 (Figure 4E).
rSlit1 had no inhibitory effect on cell migration in either PML+/ or
PML/ cells (Figure 4F).
Taken together, these results indicate that PML regulates the
migration of NPCs through repression of Slit2.
PML Regulates Slit2 via a Polycomb-Repressive-
Complex 2-Dependent Mechanism
We next sought to investigate the mechanisms underlying PML-
mediated regulation of Slit2 expression. Slit2 is a target of the
Polycomb Repressive Complex 2 (PRC2) (Yu et al., 2010), which
mediates tri-methylation of lysine 27 in histone 3 and interacts
with the oncogenic fusion protein PML-RARa as well as with
PML (Villa et al., 2007). The PRC2 regulates embryonic and adult
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neurogenesis via both cell-cycle-dependent and cell-cycle-
independent mechanisms (Hirabayashi et al., 2009; Pereira
et al., 2010; Hwang et al., 2014; Yao and Jin 2014; Zhang
et al., 2014) and affects radial migration in the cerebral cortex
(Zhao et al., 2015). We first assessed whether Slit2 is a PRC2
target in NPCs by treatingPML+/ cells with GSK343, an inhibitor
of the PRC2 catalytic subunit, EZH2 (Verma et al., 2012).
GSK343 led to a reduction in global H3K27me3 levels (Figure 5A)
and an increase of Slit2 expression (Figure 5B) as well as of the
PRC2 canonical target p16INK4a (Figure S5A).
We next performed chromatin immunoprecipitation (ChIP) to
evaluate whether PML loss affects H3K27me3 levels at the
Slit2 promoter. Indeed, PML-deficient cells displayed reduced
H3K27me3 levels at the Slit2 promoter region (Figure 5C). This
correlated with a trend in increased H3K4me3 levels (though
not statistically significant; Figure S5B). The decrease in
H3K27me3 association with the Slit2 promoter correlated with
reduced EZH2 protein levels and overall H3K27me3 levels (Fig-
ure 5D), whereas H3K27Ac and H3K4me3 levels were not
affected (Figure S5C). H3K27me3 levels were also reduced
upon acute PML loss (Figure 5E). Accordingly, PML-deficient
cells displayed increased expression of the canonical PRC2
targets E-cadherin and p16INK4a (Figures S4F and S5D).
Changes in global levels of H3K27me3 in PML/ cells corre-
lated with a reduction in H3K27me3 levels by immunofluores-
cence/confocal microscopy (Figure 5F). However, PML loss
also led to an increased accumulation of H3K27me3 at the
nuclear periphery near the NL, as detected using lamin B1 anti-
bodies (Figures 5F–5H), suggesting a role for PML in the regula-
tion of the spatial distribution of this mark within the nucleus.
In order to formally link changes in H3K27me3 to the regulation
of Slit2 expression, we tested whether Slit2 upregulation could
be abrogated by increasing H3K27me3 levels in PML-deficient
cells by using GSK-J1, an inhibitor of H3K27me3 demethylases
(Kruidenier et al., 2012; Heinemann et al., 2014). Indeed, GSK-J1
increased H3K27me3 levels in PML/ NPCs (Figure 5I) and
significantly reduced Slit2 expression (Figure 5J).
The PML/Slit Axis Regulates Cell Migration upon
RAS-Driven Neoplastic Transformation
As it has been suggested that brain cancer invasion has neuro-
biological roots, we decided to investigate whether the PML/
Slit axis regulates cell migration also upon the neoplastic trans-
formation of NPCs. PML is known to act as an effector of onco-
genic RAS for induction of cellular senescence (Alcalay et al.,
1998; Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000;
Vernier et al., 2011), but it is currently unknown whether it can
also mediate RAS oncogenic functions. Therefore, we set out
to investigate the role of a PML/Slit signaling in a model of
RAS-induced transformation of NPCs (Marumoto et al., 2009;
Bartesaghi et al., 2015). PML+/ and PML/ NPCs were trans-
duced with H-RASV12-IRES-GFP (H-RASV12) or control IRES-
GFP retroviral vectors (Figure 6A). H-RASV12 transduction was
sufficient to increase PML expression (Figure 6B). PML loss
reduced the migration of H-RASV12 NPCs (Figure 6C), similar
to that which is observed in normal NPCs. Interestingly, Slit2
was downregulated rather than upregulated in PML-deficient
H-RASV12 cells (Figure 6D), whereas expression of Slit1 was
induced (Figure 6E), suggesting that Slit1, not Slit2, is the main
target for transcriptional repression by PML upon RAS-driven
transformation.
To determine the role of PML in regulating RAS-driven trans-
formation in vivo, we performed striatal injection of H-RASV12
PML+/ and PML/ NPCs into non-obese diabetic-severe
combined immunodeficiency (NOD-SCID) mice (Table S1).
Mice (n = 10) injected with PML/ cells survived longer than
controls (n = 10; Figure 6F). Histopathological analysis showed
that cells of both genotypes had a propensity to infiltrate host tis-
sue (Figures 6Gi and 6Gii) and to give rise to poorly differentiated
intrinsic tumors expressing Nestin and PDGFRa. In contrast,
other glial tumor markers, such as GFAP, Olig2 (Figures 6G
iii–6Gx) or Sox2, or neuronal markers such as synaptophysin
and NeuN were negative (data not shown), which is in line with
a proportion of adult IDH WT (wild-type) GBM and pediatric
high-grade glioma (Louis et al., 2016). Invasiveness into adjacent
brain (Figure 6H) was significantly lower inPML/ tumors, which
showed reduced dissemination and a less pronounced single-
cell infiltration than PML+/ tumors. Finally, PML/ tumors
showed a non-statistically significant trend to be smaller than
in control tumors (Figures 6Hv–6Hvi).
An Association between PML, SLIT1, and Activation
of the RAS Pathway in GBM
In order to elucidate the role of PML in human GBM, we analyzed
the expression of PML and SLIT/ROBO family members in rela-
tion to known GBM molecular subtypes (Verhaak et al., 2010;
Brennan et al., 2013; Ceccarelli et al., 2016). PML expression
was found to be enriched in tumors belonging to the mesen-
chymal subtype (Mes; Figure S6A), which is characterized by
poor prognosis, loss or reduced expression of the RAS inhibitor
Neurofibromin 1 (NF1), and increased expression of components
of the RAS/MAPK pathway, such as FRA-1 (Figure S6B; data not
shown); (Verhaak et al., 2010). Moreover, Mes GBM showed
reduced expression of SLIT1 and conversely higher expression
of SLIT2 (Figures S6C and S6D). Accordingly, regression anal-
ysis indicated that PML expression inversely correlated with
SLIT1 and NF1 expression (Figure S6E and S6F), whereas it
directly correlated with SLIT2 and the RAS/MAPK pathway
component FRA-1 (Figure S6G; data not shown). No significant
correlation was observed with SLIT3 and ROBO family members
(data not shown).
PMLwas not expressed in human andmouse normal brain tis-
sue, as previously suggested (Regad et al., 2009), but it was ex-
pressed in human colon, and placenta were positive for PML
(data not shown). All glioma tumors included in the array were
positive for PML to various degrees (Figure S6H; Table S2) and
were categorized into either a high number of PML-positive cells
(>50%) or a low number of PML-positive cells (<50%; Figure S6I).
Tumors with high PML expression displayed a worse clinical
outcome compared with tumors with low PML expression (Fig-
ure S6J). The same could be observed when only patients with
GBM were considered (Figure S6K). Furthermore, the number
of PML-positive cells within a tumor increased between diag-
nosis and relapse in a small cohort of patient samples (Fig-
ure S6L; Table S3). These results suggest that high expression
of PML in GBM predicts a poorer clinical outcome. This is in
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Figure 3. PML Loss Impairs Migration in the RMS and Results in Smaller OB
(A and B) Shown here: (A) increased number of migratory cells in the early posterior RMS (RMSp) and (B) reduced migratory neuroblasts in the RMS adjacent the
OB (RMSob) in PML/ mice compared to PML+/ mice. Bar plots show quantification of EdU+ cells per millimeter. Scale bars, 40 mm. n = 3; unpaired t test.
(legend continued on next page)
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contrast to findings in other solid tumors, where high PML
expression has been suggested to indicate a better clinical prog-
nosis (Gurrieri et al., 2004).
PML Regulates Cell Migration in Primary Human GBM
Cells via SLIT1 Repression
We next investigated the PML/SLIT axis in a panel of primary
GBM cells isolated from human tumors, which showed variable
PML expression (Figure 7A). One of the primary human GBM
lines with high PML expression (PMLHigh G2) was transduced
with doxycycline (DOX)-inducible lentiviral vectors expressing
short hairpin (sh)RNA against PML or EGFP as control. PML
knockdown (KD) led to impaired cell migration (Figures 7B and
7C), as also observed in normal or RAS-transformed NPCs.
Furthermore, PML KD had a detrimental effect on cell growth
(Figure S6M), which was opposite of what was observed in
normal NPCs. The reduced cell migration was associated with
marked upregulation of SLIT1 mRNA (Figure 7D) and protein
levels (Figure 7H), and of ROBO2 (Figure S6N), its cognate re-
ceptor. In contrast, SLIT2 was downregulated upon PML KD,
suggesting that, like in H-RASV12-transformed NPCs, SLIT1,
not SLIT2, is the main target for PML-mediated repression
(Figure 7E). In order to functionally link SLIT1 upregulation
to impaired cell migration, we silenced SLIT1 expression by
using two different short interfering RNAs (siRNA) oligos and
performed migration assays. Notably, silencing of SLIT1 in
G2shPML rescued the migration defect, and this effect was
abrogated upon the addition of rSLIT1 (Figures 7F and S6O).
(C) The number of mature neurons within the granule cell layer (gcl) of the OB is reduced in adult PML/ compared to PML+/ mice. Graph bars show the
percentage of NeuN/EdU+ cells per olfactory bulb for each genotype of n = 3; unpaired t test. Scale bars, 100 mm.
(D) The size of the whole brain is not affected upon PML deletion. Scale bars, 5 mm. Graph bars show the brain area represented as mean ± SEM of n = 4; paired-
ratio t test.
(E) The OB size in adult PML/mice is smaller than in PML+/mice. Scale bars, 5mm.Graph bars show the ratio of OB size over the size of the whole brain. n = 4;
paired-ratio t test.
(F) PML/ NPCs isolated from the SVZ show an impaired migration in vitro compared to PML+/. n = 4; unpaired t test.
(G) Impaired migration of PML RingMutant cells. n = 3; one-way ANOVA.
(H) Supernatant from PML/ NPCs impairs migration of PML+/ NPCs. n = 3; paired Student’s t test.
All data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; n.s., non statistically significant. See also Figure S2.
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Figure 4. PML Controls Cell Migration through Repression of Slit2
(A) Slit2 mRNA is upregulated in PML/ cells compared to PML+/ cells.
(B) Slit2 increased levels in 4-OHT-treated PMLF/F compared to PMLF/WT cells. n = 3; unpaired t test.
(C and D) Slit2 is upregulated at protein levels both in PML/ (C) and in PML conditional KO cells (D).
(E) In vitro ECM assay shows that rSlit2 (100 ng/mL) impairs PML+/ cell migration and that Robo1N (200 ng/mL) rescues the impaired migration of PML/ cells.
n = 3; one-way ANOVA.
(F) rSlit1 (100 ng/mL) does not affect cell migration of both PML+/ and PML/ NPCs. n = 3; one-way ANOVA.
All data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S4.
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PML Regulates H3K27me3 Levels and Subnuclear
Distribution in Primary Human GBM Cells
PML downregulation was associated with decreased H3K27me3
levels (Figure 7G) as well as reduced expression of the PRC2
components EZH2, as observed in mouse NPCs, and SUZ12
(Figure 7H). The reduction in global H3K27me3 levels correlated
with reduced H3K27me3 at the promoters of SLIT1 and ROBO2
genes (Figure 7I). In contrast, we found an enrichment of
H3K27me3 at the promoter region of SLIT2, correlating with its
downregulation upon PML KD (Figure S6P). As observed in
normal NPCs, immunofluorescence/confocal microscopy anal-
ysis revealed a reduction of H3K27me3 signal in the nucleus of
G2shPML cells and its accumulation at the NL (Figures 7J–7L).
Immunostaining of heterochromatin protein-1a (HP-1a) did not
show redistribution to NL, suggesting that PML KD does not
lead to a general relocalization of heterochromatin to the NL
(Figure S6Q).
To further corroborate our findings, we transduced primary
human GBM cells displaying low PML expression (PMLLow G1)
with a retroviral pBABE-PML isoform I (PMLI) vector (Figure S7A).
Increased migration (Figure S7B) and reduced SLIT1 expression
(Figure 7C) correlated with increased H3K27me3 staining in the
nucleus away from the NL (Figures S7D–S7F). In contrast, a
PML mutant lacking the three major SUMOylation sites
(DSUMO1-PMLI), which are required for formation of functional
PML-NBs, did not affect H3K27me3 association with the NL,
suggesting that the effect on subnuclear distribution of chro-
matin marked by H3K27me3 is PML-NB dependent (Figures
S7D–S7F). Finally, H3K27me immunofluorescence signal was
increased upon PMLI overexpression, while DSUMO1-PMLI
had no effect (Figure S7G).
Overall, these results suggest that PML is an important regu-
lator of H3K27me3 levels as well as of the spatial distribution
of H3K27me3-marked chromatin in the nucleus.
The PML/SLIT1 Axis Controls Sensitivity of GBM Cells
to Arsenic Trioxide
It has been reported that arsenic trioxide (As2O3) targets the
oncogene PML-RARa by SUMOylation-mediated degradation
in APL (Jeanne et al., 2010; Zhang et al., 2010) and inhibits
GBM tumor growth in glioma stem cells (Zhou et al., 2015). We
found that As2O3 (0.5-mM) treatment led to PML degradation
in G2shEGFP cells, which was associated with increased PML
SUMOylation (Figure S6R). While G2shEGFP cells showed a
decrease in cell growth upon As2O3, G2shPML cells were
partially protected from drug treatment (Figures 7M and 7N).
Although SLIT ligands are involved in the regulation of prolifera-
tion during neurogenesis (Andrews et al., 2008; Borrell et al.,
2012), their role in cell survival was still unclear (Yang et al.,
2013). Therefore, we sought to investigate whether SLIT1 may
also regulate sensitivity to As2O3 treatment. Our results showed
that the addition of rSlit1 rescued cell growth upon As2O3 treat-
ment in G2shEGFP cells (Figure 7N), while it had no additive
effect in G2shPML cells. Taken together, these results indicate
that PML is required for sensitivity to As2O3 treatment in primary
humanGBMcells and that SLIT1may act as a pro-survival signal
in this context.
DISCUSSION
The present study implicates PML, a growth suppressor control-
ling embryonic neurogenesis (Salomoni and Pandolfi 2002;
Regad et al., 2009), in regulation of cell migration of NPCs via
transcriptional control of the Slit2 axon guidance gene and inde-
pendently of its ability to suppress cell cycle. Slit2 belongs to an
evolutionary conserved family of extracellular ligands involved in
repulsive axon guidance and neuronal migration control (Brose
et al., 1999; Li et al., 1999; Blockus and Che´dotal 2014) also
during SVZ neurogenesis (Nguyen-Ba-Charvet et al., 2004;
Kaneko et al., 2010). Given the potential commonalities between
neuronal migration and brain cancer invasion (Cuddapah et al.,
2014), we decided to investigate whether the PML/Slit axis could
play a pro-migratory role also upon neoplastic transformation
(Giachino et al., 2015). SLIT and ROBO genes are frequently in-
activated in human cancer via genetic and epigenetic mecha-
nisms and have been proposed to act as tumor suppressors
(Dickinson et al., 2004; Narayan et al., 2006; Dunwell et al.,
2009; Mehlen et al., 2011; Biankin et al., 2012; Go¨hrig et al.,
2014; Kong et al., 2015). In this respect, Slit and Robo suppress
migration in brain cancer cell lines (Werbowetski-Ogilvie et al.,
2006; Yiin et al., 2009). PML itself has a dual role in cancer, where
it can act as tumor suppressor downstream of oncogenic RAS
Figure 5. PML Represses Slit2 via PRC2-Mediated Histone Modification and Redistribution of H3K27me3 to the NL
(A) H3K27me3 is reduced in PML+/ NPCs treated with GSK343 (5 mM) for 72 hr and 96 hr, respectively.
(B) Increased expression of Slit2 mRNA in a time- dependent manner upon GSK343 treatment. n = 3; unpaired t test.
(C) Reduced enrichment of H3K27me3 on the promoter of Slit2 in PML/ cells. n = 3; unpaired t test.
(D) Western blotting (WB) analysis of nuclear extracts from PML+/ and PML/ cells showing reduced H3K27me3 and EZH2 levels in PML/ cells. Bar plots
represent densitometric analysis of H3K27me3 levels normalized to total H3 and EZH2 levels normalized to b-actin. n = 3; unpaired t test.
(E) Reduction of H3K27me3 in PML conditional KO system after treatment with 4-OHT.
(F) Representative confocal images of the H3K27me3 redistribution to the NL in PML/ cells. Cells were stained for H3K27me3 (green), LMNB1 (red), and
nucleus (blue Hoechst dye). Yellow line indicates the orientation of the line scan profile. Scale bars, 2 mm.
(G) Panels showing separate channels at higher magnification. Arrowheads in the third bottom panel show the redistribution of H3K27me3 at NL in PML/ cells.
Scale bars, 0.5 mm. The cartoons show the distribution of the histone mark H3K27me3 in the NL in PML+/ and PML/ cells.
(H) Quantification per pixel of H3K27me3 at the NL in PML+/ and PML/ cells. Bar plots represent the mean gray value of 13 images analyzed per condition;
unpaired t test.
(I) Inhibition of JMJD3 and UTX in PML/ NPCs rescues H3K27me3 levels. Cells were treated with GSK-J1 (50 nM) for 48 hr. Bar plots represent densitometric
analysis of H3K27me3 levels normalized to total H3.
(J) Slit2 mRNA expression is reduced upon GSK-J1 treatment in PML/ NPCs. n = 3; one-way ANOVA.
All data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S5.
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Figure 6. The PML/Slit Axis Regulates Cell Migration upon RAS-Driven Neoplastic Transformation
(A) WB analysis of the efficiency of the H-Rasv12-IRES-GFP retroviral vector.
(B) Oncogenic H-Rasv12 increases PML expression in normal NPCs (asterisks indicate specific bands).
(legend continued on next page)
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(Alcalay et al., 1998; Fogal et al., 2000; Guo et al., 2000; Pearson
et al., 2000; Vernier et al., 2011) or promote tumorigenesis (Ito
et al., 2008; Carracedo et al., 2012; Ito et al., 2012). As enhanced
RAS/MAPK signaling has been proposed to contribute to GBM
development (Shannon et al., 2005; Marumoto et al., 2009;
Brennan et al., 2013), we investigated the impact of PML loss
in NPCs upon expression of an oncogenic RAS mutant.
PML loss impaired cell migration of RAS-transformed NPCs
in vitro as well as upon transplantation into the brain of recipient
mice. Overall, these data suggest an oncogenic role of PML in
CNS tumorigenesis. Accordingly, PML protein expression is
increased in grade IV glioma compared to grade III astrocytoma
and oligodendroglioma tumors and correlates with poor overall
survival. Furthermore, PML expression is enriched in the Mes
subtype of GBM, which is defined by poor survival, RAS/MAPK
activation, impaired p53 and pRb pathways, and a gene expres-
sion signature related to cell migration and angiogenesis (Ver-
haak et al., 2010; Brennan et al., 2013). Interestingly, in PML-
deficient RAS-transformed NPCs and PML KD primary GBM
cells, Slit1 was upregulated, whereas Slit2 was downregulated,
unlike in normal NPCs, where Slit2 is the main target for PML-
mediated repression. PML and SLIT1 were inversely correlated
in Mes GBM tumors, while SLIT2 was highly expressed in the
Mes subtype and directly correlated with PML expression. It is
possible that SLIT2 may be unable to repress cell migration
and/or may bear pro-tumor functions in GBM (e.g., angiogenesis
and/or proliferation), thus potentially explaining its elevated
levels in Mes tumors.
With respect to mechanisms underlying PML-mediated
repression of Slit genes, our findings suggest that PML re-
presses Slit2 by controlling EZH2-mediated tri-methylation of
lysine 27 in the histone 3 tail. EZH2 has been previously impli-
cated in the regulation of neurogenesis (Hirabayashi et al.,
2009; Pereira et al., 2010; Hwang et al., 2014; Yao and Jin
2014; Zhang et al., 2014), cortex development (Pereira et al.,
2010; Zhang et al., 2014), and radial migration (Zhao et al.,
2015). Given that EZH2 protein levels are decreased in PML-defi-
cient cells, one could hypothesize that PML interaction with
EZH2 (Villa et al., 2007) could affect its stability or nuclear
distribution. Additional mechanisms may also be involved, since
PML downregulation induces not only a reduction in nuclear
H3K27me3 levels but also its redistribution to the nuclear lamina
(NL) in both mouse NPCs and human GBM cells. The NL pro-
vides anchorage for transcriptionally inactive heterochromatin,
as well as histones and transcription factors, and contributes
to maintain the spatial localization of the repressive H3K9me3
and H3K27me3 histone marks in regions called lamina-associ-
ated domains (LADs) (Guelen et al., 2008; Towbin et al., 2012;
Kind et al., 2013; Sadaie et al., 2013; Shah et al., 2013; Harr
et al., 2015, 2016). The role of NL in chromatin organization
has been implicated in several cellular functions as differentia-
tion, senescence, and aging through its ability to affect transcrip-
tion (Scaffidi and Misteli 2008; Peric-Hupkes et al., 2010; Lund
et al., 2015). Future investigations will help in defining how
PML could lead to the reorganization of H3K27me3-marked
heterochromatin to the NL and how this relates to changes in
transcription at SLIT1 and SLIT2 loci. PML has been reported
to control centromeric heterochromatin remodeling in centro-
meric instability and facial dysmorphy (ICF) cells (Luciani et al.,
2006), and, interestingly, in early differentiating human embry-
onic stem cells (hESCs), PML regulates nuclear architecture,
potentially via interaction with the NL (Butler et al., 2009).
Furthermore, PML isoform II has been shown to accumulate at
the NL (Jul-Larsen et al., 2010). As we did not detect total PML
or PML-II (data not shown) at the NL, alternative mechanisms
are likely involved. In this respect, a recent study implicated
PML in the maintenance of heterochromatin integrity via modu-
lation of H3K9me3/H3K27me3 balance at heterochromatic
PML-associated domains (PADs). Specifically, PML loss leads
to a shift of histone methylation from H3K9me3 to H3K27me3
at PADs (Delbarre et al., 2017), potentially linked to its ability to
interact with the H3.3 chaperone complex ATRX/DAXX (Salo-
moni, 2013; Delbarre et al., 2017). It would be interesting to
determine whether H3K27me3-enriched PADs relocate to NL
upon PML downregulation/loss. As functional and evolutionary
conserved interaction has been described between lamin A/C
and PcG proteins (Cesarini et al., 2015; Marullo et al., 2016),
one could hypothesize that, despite the global reduction of
EZH2 level/activity in PML-deficient cells, there could be a reloc-
alization of EZH2 to the NL, resulting in enrichment of H3K27me3
and repression of genes associated at this location. In this
respect, SLIT2 could be one of the genes relocating to NL for
transcriptional repression upon PML KD.
The concept that PML bears an oncogenic role in GBM is also
supported by the reduced growth of primary GBM cells we
observed upon PML KD. This, along with the pro-migratory
role in GBM cells, makes PML a promising/potential therapeutic
target to compromise tumor growth and brain parenchyma
invasiveness, which are responsible for the aggressiveness of
high-grade glioma (Furnari et al., 2007; Cuddapah et al., 2014).
(C) In vitro ECM assay in PML+/ H-Rasv12 and PML/ H-Rasv12 cells displays an impaired migration of PML/ H-Rasv12 NPCs. n = 4; one-way ANOVA test.
(D and E) Shown here: (D) reduced Slit2 and (E) increased Slit1 mRNA levels in transformed PML/ H-Rasv12 compared to PML+/ H-Rasv12 NPCs. n = 3;
unpaired t test.
(F) Kaplan-Meier curve showing the overall survival of NOD/SCID immunosuppressed mice injected with transformed PML+/ H-Rasv12 and PML/ H-Rasv12
cells. p = 0.0002, log rank (Mantel-Cox test).
(G) Orthotopic allografts fromPML+/H-Rasv12 (left) andPML/H-Rasv12 (right): i and ii, H&E-stained grafts, showing an infiltrative tumormargin inPML+/ grafts
and a more sharply delineated border in PML/ tumors. Grafted tumor cells express no GFAP (iii and iv), low levels of Nestin (v and vi), moderate levels of
PDGFRa (vii and viii), and no Olig2 (ix and x). Scale bar, 100 mm.
(H) Image analysis of invasiveness of PML+/ H-Rasv12 (left) and PML/ H-Rasv12 (right). Tumor cells are identified by immunostaining for GFP. (i and ii) Red
boxes identify areas shown in iii and iv. (iii and iv) Image analysis identifies non-infiltrated host (unlabeled), overall infiltrated area (green), and core tumor area
(blue). (v)PML+/H-Rasv12 tumor shows significantly higher tumor cell migration into the host thanPML/H-Rasv12 tumors. (vi) Although PML+/H-Rasv12 tumor
occasionally grew larger than PML/ H-Rasv12 tumors, this difference was non-significant.
All data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Table S1.
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Figure 7. PML Regulates Cell Migration in Primary GBM Cells via Repression of Slit1 in a PRC2-Dependent Manner and H3K27me3 Nuclear
Periphery Redistribution
(A) PML is expressed at variable levels in GBM cells isolated from patients with glioma (G1, G2, G3, G4, G7, G166, G144, and GSP). Asterisks indicate specific
bands.
(B) PML KD in G2shEGFP and G2shPML cells. Asterisks indicate specific bands.
(C) In vitro ECM assay reveals an impaired migration of G2shPML cells. n = 3; unpaired t test.
(D and E) Shown here, (D) Slit1 expression is upregulated, and (E) Slit2 expression is reduced in G2shPML compared to G2shEGFP cells. n = 5 and n = 6,
respectively; unpaired t test.
(F) siSlit1 rescues the impaired migration of G2shPML cells; the addition of rSlit1 reverts this effect. n = 3; one-way ANOVA.
(G) H3K27me3 global levels are reduced in G2shPML compared to G2shEGFP. Bar plots represent the densitometric analysis of H3K27me3/H3. n = 3; unpaired
t test.
(legend continued on next page)
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As2O3 induces PML SUMOylation and subsequent degradation
in APL and in GBM stem cells (Jeanne et al., 2010; Zhang
et al., 2010; Zhou et al., 2015). Our work demonstrates that pro-
longed As2O3 treatment reduces the viability of GBM cells, while
loss of PML or stimulation with recombinant SLIT1 confers resis-
tance to treatment. Based on these findings, one could specu-
late that tumors carrying high PML and low SLIT1 levels (e.g.,
Mes GBM) could be particularly sensitive to As2O3.
Altogether, this study suggests that fundamental mechanisms
controlling cell migration during adult neurogenesis can be
hijacked upon neoplastic transformation and identifies PML as
a potential therapeutic target in GBM.
EXPERIMENTAL PROCEDURES
Statistics
All experiments were performed in triplicate for each condition unless
otherwise specified. Statistical analysis was carried out using GraphPad
Prism v.6 (GraphPad Software). All values and graphs were expressed as
mean ± SEM. Student’s t test was performed unless otherwise specified. A
statistically significant difference was indicated by a p value less than 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.06.047.
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